Area deprivation and rurality impact overall survival and adjuvant therapy administration in patients with pancreatic ductal adenocarcinoma (PDAC)

被引:2
|
作者
Pothuri, Vikram [1 ]
Rodriguez, Jorge G. Zarate [1 ]
Kasting, Christina [1 ]
Leigh, Natasha [1 ,2 ]
Hawkins, William G. [1 ,2 ]
Sanford, Dominic E. [1 ,2 ]
Fields, Ryan C. [1 ,2 ,3 ]
机构
[1] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[2] Washington Univ, Alvin J Siteman Comprehens Canc Ctr, Sch Med, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave Campus Box 8109, St Louis, MO 63110 USA
关键词
RACIAL DISPARITIES; CANCER;
D O I
10.1016/j.hpb.2023.08.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The impact of neighborhood deprivation on outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) is not well-described and represents an area to improve disparities.Methods: We retrospectively queried our prospectively maintained database of patients with PDAC (2014-2022). Patients were grouped by Area Deprivation Index (ADI) and rural-urban commuting area (RUCA) codes. Cox proportional hazards models and logistic regressions were used to investigate effect on overall survival (OS) and adjuvant therapy administration.Results: 536 patients were included. High ADI patients (more disadvantaged, n = 184) were more likely to identify as non-Hispanic Black (17.9% vs. 4.8%, p < 0.01) and were more likely to be from rural areas (49.5% vs. 18.5%, p < 0.01). High ADI was independently associated with decreased OS (HR (95% CI): 1.31 (1.01-1.69), p = 0.04). Urban high ADI patients were 3.5 times more likely to receive adjuvant therapy than rural high ADI patients (OR [95% CI]: 3.48 [1.26-9.61], p = 0.02).Conclusion: Patients from the most disadvantaged neighborhoods have decreased OS. Access to adjuvant therapy likely contributes to this disparity in rural areas. Investigation into sources of this OS disparity and identification of barriers to adjuvant therapy will be crucial to improve outcomes in un-derserved patients with PDAC.
引用
收藏
页码:1545 / 1554
页数:10
相关论文
共 50 条
  • [1] Area Deprivation and Rurality Impact Overall Survival and Adjuvant Therapy Administration in Patients with Pancreatic Ductal Adenocarcinoma after Surgical Resection
    Pothuri, Vikram
    Kasting, Christina
    Rodriguez, Jorge
    Leigh, Natasha
    Sanford, Dominic E.
    Hawkins, William G.
    Fields, Ryan C.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S448 - S449
  • [2] Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)
    Pitiyarachchi, O.
    Lin, F. P.
    Spooner, A.
    Sharbeen, G.
    Barker, H. P.
    Thornton, K.
    Collignon, E.
    Ballinger, M. L.
    Thomas, D. M.
    Magenau, A.
    Porazinski, S.
    Raina, A.
    Sjoquist, K. M.
    Chantrill, L. A.
    Gebski, V.
    Sowmya, A.
    Timpson, P.
    Pajic, M.
    Goldstein, D.
    Phillips, P. A.
    ANNALS OF ONCOLOGY, 2024, 35 : S925 - S925
  • [3] Survival impact and predictive scores for thrombosis associated with pancreatic ductal adenocarcinoma (PDAC)
    Romano, A.
    Gavira, J.
    Villalba, A.
    Sanz, J.
    Molina, M.
    Bosma, F.
    Sanchez, S.
    Tapia, J.
    Piedra, A.
    Aguado, M.
    Pelegrin, F.
    Martin-Cullell, B.
    Teres, R.
    Paez, D.
    Cerda, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S114 - S114
  • [4] Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC)
    Andre Alabd
    Andrew Alabd
    Oloruntoba Bolaji
    Kavin Sugumar
    John Ammori
    Jeffrey Hardacre
    Jordan M. Winter
    Annals of Surgical Oncology, 2021, 28 : 1060 - 1068
  • [5] Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC)
    Alabd, Andre
    Alabd, Andrew
    Bolaji, Oloruntoba
    Sugumar, Kavin
    Ammori, John
    Hardacre, Jeffrey
    Winter, Jordan M.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (02) : 1060 - 1068
  • [6] Effect of chemotherapy on survival of patients with recurrent pancreatic ductal adenocarcinoma (PDAC) following surgical therapy.
    Gbolahan, Olumide B.
    Tong, Yan
    O'Neil, Bert H.
    Shanda, Safi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC).
    Mehdi, Maahum
    Kamgar, Mandana
    George, Ben
    Szabo, Aniko
    Annunzio, Kaitlin
    Taylor, Bradley W.
    Shreenivas, Aditya Varnam
    Chakrabarti, Sakti
    Thomas, James P.
    Tsai, Susan
    Christians, Kathleen K.
    Evans, Douglas B.
    Clarke, Callisia
    Hall, William Adrian
    Erickson, Beth
    Ahmed, Gulrayz
    Thapa, Bicky
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Adjuvant therapy (AT) following resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged?
    Bertens, Kimberly A.
    Massman, John
    Garbus, Samuel
    Mandelson, Margaret T.
    Lin, Bruce
    Picozzi, Vincent J.
    Alseidi, Adnan
    Biehl, Thomas
    Helton, William Scott
    Rocha, Flavio G.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [9] Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods
    Mora, Javier
    Krepline, Ashley N.
    Aldakkak, Mohammed
    Christians, Kathleen K.
    George, Ben
    Hall, William A.
    Erickson, Beth A.
    Kulkarni, Naveen
    Evans, Douglas B.
    Tsai, Susan
    AMERICAN JOURNAL OF SURGERY, 2021, 222 (01): : 10 - 17
  • [10] Neo-adjuvant Therapy (NAT) for Pancreatic Ductal Adenocarcinoma (PDAC) and Improvement in Glycemic Parameters
    Vasavada, S.
    Khan, A.
    Chari, S. T.
    PANCREAS, 2021, 50 (07) : 1106 - 1106